Fagron N.V. : More cautious on 2H21 REBITDA following inflation
>Inflation likely to push REBITDA below FY21 guidance: AAOBe €116m - Fagron is set to report its 3Q21 trading update on 13 October. During the company’s 1H21 results presentation, Fagron guided for FY21 REBITDA of €118-124m. Two factors lead us to believe that this range will likely prove to be ambitious, being 1/ inflation, and 2/ (to a much lesser extent) the impact of the Delta-variant in the US. In Europe, Fagron cannot always immediately pass-on price increases t...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.